Blood-based score to diagnose idiopathic nephrotic syndrome without a kidney biopsy
Tests a diagnostic score for idiopathic nephrotic syndrome in adults, avoiding kidney biopsy.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes
- Status
- Recruiting
- People taking part
- 265 people, planned
- Started
- 15 Apr 2025
- Expected to end
- Aug 2027
- Type of study
- Observational
- Record updated
- 14 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital with a first episode of nephrotic syndrome who need a kidney biopsy. It tests a score that may allow diagnosis without a biopsy.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- First episode of nephrotic syndrome needing hospital care: protein in urine greater than 3g/g and albumin level < 30g/L.
- Biomarker or test result
- Negative anti-PLA2r antibodies in the blood.
Main reasons for not taking part
- Known lupus kidney disease (lupus nephropathy) before the current episode
- Known IgA nephropathy before the current episode
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients aged 18 years and older
- Hospitalized for a first episode of nephrotic syndrome (proteinuria greater than 3g/g and albumin level < 30g/L)
- Negative anti-PLA2r antibodies in the blood
- Requirement for a renal biopsy for diagnostic purposes
Who cannot take part
- Patients with known lupus nephropathy (prior to the current episode)
- Patients with known IgA nephropathy (prior to the current episode)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Renal biopsy (RB) is the reference diagnostic procedure for Idiopathic Nephrotic Syndrome (INS). It is an invasive procedure, particularly risky during the acute phase of nephrotic syndrome when anticoagulation therapy is required.
Read full original descriptionShow less
By identifying serum antibodies that allow for the non-invasive diagnosis of the main differential diagnoses of INS, (Membranous Nephropathy), the development of a non-invasive diagnostic tool for INS could help reduce the morbidity associated with the invasive renal biopsy procedure, minimizing the risk of incorrect diagnosis. We developed a diagnostic score, the SNIT, from routine clinical and biological variables to allow INS diagnoses in patients for whom detection of blood antibodies of Membranous Nephropathy were negative. The main goal of this study is to validate this diagnosis score in a prospective study, to allow INS diagnosis without renal biopsy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes : DNI-SNI
- Plain-language title
- Blood-based score to diagnose idiopathic nephrotic syndrome without a kidney biopsyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 14 August 2025